Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name LY3200882
Trade Name
Synonyms LY 3200882
Drug Descriptions

LY3200882 is a small molecule that inhibits TGFBR1, potentially resulting in increased anti-tumor immune response and decreased tumor growth (AACR Annual Meeting 2017, Abstract nr 955).

DrugClasses TGFBR1 inhibitor 16
CAS Registry Number 1898283-02-7
NCIT ID C132013


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Gemcitabine + LY3200882 + Nab-paclitaxel Gemcitabine LY3200882 Nab-paclitaxel 0 0
LY3200882 LY3200882 0 1
LY3200882 + LY3300054 LY3200882 LY3300054 0 0
LY3200882 + Pembrolizumab LY3200882 Pembrolizumab 0 1

Additional content available in CKB BOOST